Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...

Hypercalcaemia is a common clinical condition in hospitalized patients. Malignancies and primary hyperparathyroidism (PHPT) are the two most common causes of hypercalcaemia in hospitalized patients.1–3 Apparently, there is a changing profile of hypercalcaemia in India, especially in hospital settings, because ...

Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1 It has two forms: the first is a membrane-bound form, which ...

Polycystic ovary syndrome (PCOS) is a multifactorial, multifaceted syndrome that affects women across all ages from adolescence to post-menopause. It is reported to be the most common endocrinopathy in women of the reproductive age group.1 The nature of this syndrome ...

‘Closed-loop’ systems mark a significant advancement in managing type 1 diabetes. These systems which continuously monitor glucose levels and automatically deliver insulin through a pump, help many individuals with type 1 diabetes maintain optimal glucose levels with greater ease. In this episode, we explore the progress, challenges and impact of these innovative technologies with Endocrinology Clinical Pharmacy Specialist, Dr Diana Isaacs, and highlight their future potential.

Hyperthyroidism is prevalent in 0.1–2.5% of the population, and Graves’ disease is diagnosed in 80% of patients with hyperthyroidism.1,2 This condition arises from the uncontrolled, excessive activation of the thyroid-stimulating hormone (TSH) receptor by autoreactive TSH-receptor antibodies.2 Elevated thyroid hormones in hyperthyroidism ...

Thyroid nodules are common worldwide, and their prevalence is increasing. Most nodules are asymptomatic and detected incidentally on cross-sectional imaging or physical examination. In rare cases (10–15%), nodules are malignant and require diagnostic evaluation. Even malignant nodules frequently show non-aggressive behaviour.1 ...

Metformin Metformin has been recommended as the first-line glucose-lowering agent for the management of type 2 diabetes (T2D) for several decades due to its efficacy and safety profile.1–3 In fact, metformin has been widely used as an insulin-sensitizing agent for ...

Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1 Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and ...

Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...

Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1 Closely linked to T2D is metabolic dysfunction-associated steatotic ...

Cushing’s disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, or rarely carcinoma, and is considered a highly morbid endocrine disorder with few medical options.1,2 Although transsphenoidal pituitary surgery (TSS) is the mainstay of treatment for ...